250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO, CA
Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
Investor Presentation
Septerna Begins Phase 1 Trial of SEP-631 for Mast Cell Diseases
Highlights Business Progress and Reports Second Quarter 2025 Financial Results
Changes in Board, Management or Compensation
Other Events
Shareholder votes
Earnings Release
Q2
Q1
FY 2024
Q3
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Certificate
Registration of Securities
Amended Registration Statement for Securities
S-1
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
S-1MEF